Literature DB >> 12373559

Deep brain stimulation of the subthalamic nucleus versus levodopa challenge in Parkinson's disease: measuring the on- and off-conditions with FDG-PET.

R Hilker1, J Voges, A Thiel, M Ghaemi, K Herholz, V Sturm, W-D Heiss.   

Abstract

In order to compare the effects of high-frequency stimulation of the subthalamic nucleus (STN-DBS) and a levodopa-challenge on cerebral metabolic activity, we conducted PET scans with [(18)F]2-fluoro-2-deoxyglucose (FDG) in the drug- and stimulation- on- and off-condition in a single patient suffering from advanced PD. Our data revealed evidence for improved thalamocortical processing released from inhibition by overactive basal ganglia output nuclei in both on-conditions. While levodopa also led to a reduction of lentiform hyperactivity, effective STN stimulation seemed to interfere with distinct cerebellar and limbic circuits.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12373559     DOI: 10.1007/s00702-002-0696-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  18 in total

Review 1.  Network effects of deep brain stimulation.

Authors:  Ahmad Alhourani; Michael M McDowell; Michael J Randazzo; Thomas A Wozny; Efstathios D Kondylis; Witold J Lipski; Sarah Beck; Jordan F Karp; Avniel S Ghuman; R Mark Richardson
Journal:  J Neurophysiol       Date:  2015-08-12       Impact factor: 2.714

2.  Does subthalamic nucleus stimulation affect the frontal limbic areas? A single-photon emission computed tomography study using a manual anatomical segmentation method.

Authors:  C Haegelen; M Verin; B Aubert Broche; F Prigent; P Jannin; B Gibaud; X Morandi
Journal:  Surg Radiol Anat       Date:  2005-09-14       Impact factor: 1.246

3.  Network modulation in the treatment of Parkinson's disease.

Authors:  Kotaro Asanuma; Chengke Tang; Yilong Ma; Vijay Dhawan; Paul Mattis; Christine Edwards; Michael G Kaplitt; Andrew Feigin; David Eidelberg
Journal:  Brain       Date:  2006-07-14       Impact factor: 13.501

4.  Common and unique responses to dopamine agonist therapy and deep brain stimulation in Parkinson's disease: an H(2)(15)O PET study.

Authors:  Trent J Bradberry; Leonard Verhagen Metman; José L Contreras-Vidal; Pepijn van den Munckhof; Lara A Hosey; Jennifer L W Thompson; Geralyn M Schulz; Fredrick Lenz; Rajesh Pahwa; Kelly E Lyons; Allen R Braun
Journal:  Brain Stimul       Date:  2011-10-05       Impact factor: 8.955

Review 5.  Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease.

Authors:  Shigeki Hirano; Thomas Eckert; Toni Flanagan; David Eidelberg
Journal:  Mov Disord       Date:  2009       Impact factor: 10.338

Review 6.  Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson's disease.

Authors:  Shichun Peng; David Eidelberg; Yilong Ma
Journal:  Neurosci Bull       Date:  2014-09-28       Impact factor: 5.203

7.  Advanced research on deep brain stimulation in treating mental disorders.

Authors:  Dongxin Wang; Xuejun Liu; Bin Zhou; Weiping Kuang; Tiansheng Guo
Journal:  Exp Ther Med       Date:  2017-10-24       Impact factor: 2.447

8.  Changes in network activity with the progression of Parkinson's disease.

Authors:  Chaorui Huang; Chengke Tang; Andrew Feigin; Martin Lesser; Yilong Ma; Michael Pourfar; Vijay Dhawan; David Eidelberg
Journal:  Brain       Date:  2007-04-30       Impact factor: 13.501

9.  SPECT and PET analysis of subthalamic stimulation in Parkinson's disease: analysis using a manual segmentation.

Authors:  Claire Haegelen; Daniel García-Lorenzo; Florence Le Jeune; Julie Péron; Bernard Gibaud; Laurent Riffaud; Gilles Brassier; Christian Barillot; Marc Vérin; Xavier Morandi
Journal:  J Neurol       Date:  2009-09-23       Impact factor: 4.849

10.  Deep brain stimulation exacerbates hypokinetic dysarthria in a rat model of Parkinson's disease.

Authors:  Nathaniel O King; Collin J Anderson; Alan D Dorval
Journal:  J Neurosci Res       Date:  2015-10-26       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.